Atapol Sughondhabirom

Bangkok, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Immune cell exhaustion and apoptotic markers in major depressive disorder: Effects of in vitro cannabidiol administration.

Immune cell exhaustion and apoptotic markers in major depressive disorder: Effects of in vitro cannabidiol administration.

Journal: Brain, behavior, & immunity - health

Published: January 11, 2025

T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression.

T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression.

Journal: Scientific reports

Published: November 26, 2023

Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviours.

Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviours.

Journal: Acta neuropsychiatrica

Published: September 08, 2023

T cell activation and lowered T regulatory cell numbers are key processes in severe major depressive disorder: Effects of recurrence of illness and adverse childhood experiences.

T cell activation and lowered T regulatory cell numbers are key processes in severe major depressive disorder: Effects of recurrence of illness and adverse childhood experiences.

Journal: Journal of affective disorders

Published: September 05, 2023

Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness.

Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness.

Journal: Brain sciences

Published: June 03, 2023

Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles.

Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles.

Journal: Cells

Published: March 30, 2022

The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.

The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.

Journal: Cells

Published: March 10, 2022

In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.

In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 07, 2022

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.

Journal: The Australian and New Zealand journal of psychiatry

Published: June 06, 2017

Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.

Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.

Journal: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Published: March 21, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026